

## Opis choroby \*

### Definicja

A teratogenic embryofetopathy that results from maternal exposition to methimazole (MMI; or the parent compound carbimazole) in the first trimester of pregnancy. MMI is an antithyroid thionamide drug used for the treatment of Graves' disease. In the infant, MMI may result in choanal atresia, esophageal atresia, omphalocele, omphalomesenteric duct anomalies, congenital heart disease (such as ventricular septal defect), renal system malformations and aplasia cutis. Additional features that may be observed include facial dysmorphism (short upslanting palpebral fissures, a broad nasal bridge with a small nose and a broad forehead) and athelia/hypothelia.

### Dane

#### Klasyfikacja

Zespół wad wrodzonych MMI/CMZ embryofetopathy

#### Synonimy

Embriopatia metimazolowa/karbamizolowa  
Embriofetopatia metimazolowa/karbamizolowa  
MMI/CMZ embryopathy  
Methimazole/carbimazole embryofetopathy  
Methimazole/carbimazole embryopathy

#### Kod ORPHA

1923

#### Kod OMIM

-

#### Kod ICD10

Q86.8

#### Kod ICD11

LD2F.0Y

---

#### \*Źródło

orphanet